Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 11, 2024 05:15 ET | Source: Research and Markets

Global Epigenetics Strategic Research Report 2024: Market to Grow by $2.3 Billion to 2030 - Rising Demand for Non-Invasive Epigenetic Testing Methods Drives Adoption

Dublin, July 11, 2024 (GLOBE NEWSWIRE) -- The "Epigenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Epigenetics is...
July 08, 2024 07:00 ET | Source: iTeos Therapeutics Inc.

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and...
June 11, 2024 08:15 ET | Source: Skyhawk Therapeutics

Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman

BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets,...
June 03, 2024 08:15 ET | Source: Furrever Token

The Cryptocurrency You Shouldn't Miss Next to Bitcoin and Solana! Which Cryptocurrency Will Shape Your Future?

New York City, NY, June 03, 2024 (GLOBE NEWSWIRE) -- As Bitcoin, Ethereum and Solana proceed to be the cornerstones of the cryptocurrency advertise, a modern player, Furrever Token, has...
May 27, 2024 03:01 ET | Source: Research and Markets

Antibiotic Resistance Markets Therapeutics, by Pathogen and Therapy Type to 2027: Search for Alternatives to Antibiotics Creates New Global Goldrush

Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization....
May 14, 2024 13:57 ET | Source: Voltalia

Voltalia lance son troisième plan d’actionnariat salarié

Voltalia lance son troisième plan d’actionnariat salarié Voltalia (Euronext Paris, ISIN code : FR0011995588), acteur international des énergies renouvelables, annonce la mise en œuvre de son...
May 10, 2024 08:26 ET | Source: iTeos Therapeutics Inc.

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor...
May 08, 2024 07:25 ET | Source: Research and Markets

$2.75+ Epigenetic Markets - Global Industry Size, Share, Trends, Opportunity, and Forecasts, 2019-2023 & 2024-2029F

Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Epigenetic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's...
April 26, 2024 09:23 ET | Source: Believe

COMMUNIQUÉ DU 26 AVRIL RELATIF AU DÉPÔT DU PROJET DE NOTE ÉTABLI PAR LA SOCIÉTÉ BELIEVE EN RÉPONSE À L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉ BELIEVE INITIÉE PAR UPBEAT BIDCO

COMMUNIQUÉ DU 26 AVRIL RELATIF AU DÉPÔT DU PROJET DE NOTE ÉTABLI PAR LA SOCIÉTÉ EN RÉPONSE À L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉ BELIEVE INITIÉE PAR ...
April 26, 2024 09:20 ET | Source: Upbeat Bidco

COMMUNIQUE RELATIF AU DEPOT D’UN PROJET D’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE visant les actions de la société Believe initiée par Upbeat BidCo SAS

PRIX DE L’OFFRE : 15€ par action Believe DURÉE DE L’OFFRE : 15 jours de négociation Le calendrier de l’offre publique d’achat simplifiée (l’« Offre ») sera déterminé par l’Autorité des marchés...